Defined Flanking Spacers and Enhanced Proteolysis Is Essential for Eradication of Established Tumors by an Epitope String DNA Vaccine1
暂无分享,去创建一个
Larry R. Smith | P. Kloetzel | Markwin P. Velders | Sanne Weijzen | Gretchen L. Eiben | Amira G. Elmishad | Peter-M. Kloetzel | Terry Higgins | Richard B. Ciccarelli | Mererid Evans | Stephen Man | Larry Smith | W. Martin Kast | W. Kast | R. Ciccarelli | G. L. Eiben | M. Evans | M. Velders | S. Weijzen | A. G. Elmishad | T. Higgins | S. Man
[1] G. Fleuren,et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. , 1999, European journal of cancer.
[2] L. Kinlen. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. , 1985, The American journal of medicine.
[3] R. Schlegel,et al. The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes , 1989, Journal of virology.
[4] M. Feltkamp,et al. Vaccination with cytotoxic T lymphocyte epitope‐containing peptide protects against a tumor induced by human papillomavirus type 16‐transformed cells , 1993, European journal of immunology.
[5] S J Rodda,et al. Mapping the major human T helper epitopes of tetanus toxin. The emerging picture. , 1993, Journal of immunology.
[6] P. Greenberg,et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein , 1991, The Lancet.
[7] F. Wiklund,et al. Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. , 1999, The New England journal of medicine.
[8] Virander S. Chauhan,et al. "Universal" T helper cell determinants enhance immunogenicity of a Plasmodium falciparum merozoite surface antigen peptide. , 1992, Journal of immunology.
[9] K. Münger,et al. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. , 1989, Science.
[10] J. Kaplan,et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. , 1999, Journal of immunology.
[11] J. Whitton,et al. A "string-of-beads" vaccine, comprising linked minigenes, confers protection from lethal-dose virus challenge , 1993, Journal of virology.
[12] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[13] J. Ulmer,et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. , 1993, Science.
[14] G Y Ishioka,et al. Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. , 1999, Journal of immunology.
[15] Fernando Rodriguez,et al. DNA Immunization with Minigenes: Low Frequency of Memory Cytotoxic T Lymphocytes and Inefficient Antiviral Protection Are Rectified by Ubiquitination , 1998, Journal of Virology.
[16] H. Schreiber,et al. Active immunization against cancer cells: impediments and advances. , 1998, Seminars in oncology.
[17] Genital human papillomavirus infection in female university students as determined by a PCR-based method. , 1991, JAMA.
[18] D J Moss,et al. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[19] I. Frazer,et al. A "public" T-helper epitope of the E7 transforming protein of human papillomavirus 16 provides cognate help for several E7 B-cell epitopes from cervical cancer-associated human papillomavirus genotypes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Feltkamp,et al. Major differences in transporter associated with antigen presentation (TAP)-dependent translocation of MHC class I-presentable peptides and the effect of flanking sequences. , 1995, Journal of immunology.
[21] P. Kloetzel,et al. The cleavage preference of the proteasome governs the yield of antigenic peptides , 1995, The Journal of experimental medicine.
[22] Catia,et al. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.
[23] A. Levine,et al. Association of human papillomavirus types 16 and 18 E6 proteins with p53. , 1990, Science.
[24] S. H. van der Burg,et al. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16‐induced tumors , 1995, European journal of immunology.
[25] S. Wilczynski,et al. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] A Sette,et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. , 1994, Journal of immunology.
[27] B. Moss,et al. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination , 1988, Journal of virology.
[28] W Keilholz,et al. Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[29] J. Drijfhout,et al. Human leukocyte antigen-A2.1 restricted candidate cytotoxic T lymphocyte epitopes of human papillomavirus type 16 E6 and E7 proteins identified by using the processing-defective human cell line T2. , 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[30] Anderson Ll,et al. Multivalent minigene vaccines against infectious disease. , 1999 .
[31] E. Wherry,et al. Point mutation flanking a CTL epitope ablates in vitro and in vivo recognition of a full-length viral protein. , 1997, Journal of immunology.
[32] P. Kloetzel,et al. The Sequence Alteration Associated with a Mutational Hotspot in p53 Protects Cells From Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope , 1998, The Journal of experimental medicine.
[33] P M Kloetzel,et al. Abrogation of CTL Epitope Processing by Single Amino Acid Substitution Flanking the C-Terminal Proteasome Cleavage Site1 , 2000, The Journal of Immunology.
[34] E. Gilboa,et al. Induction of Cytotoxic T Lymphocytes With Dendritic Cells Transfected With Human Papillomavirus E6 and E7 RNA: Implications for Cervical Cancer Immunotherapy , 2000, Journal of immunotherapy.
[35] D. Carson,et al. Costimulation provided by DNA immunization enhances antitumor immunity. , 1997, Journal of immunology.
[36] P. Kloetzel,et al. A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. , 1999, Journal of molecular biology.
[37] R. Germain,et al. Predominant Role for Directly Transfected Dendritic Cells in Antigen Presentation to CD8+ T Cells after Gene Gun Immunization , 1998, The Journal of experimental medicine.
[38] S. Childs. Aztreonam in the treatment of urinary tract infection. , 1985, The American journal of medicine.
[39] Scott R. Burrows,et al. Targeting a Polyepitope Protein Incorporating Multiple Class II-Restricted Viral Epitopes to the Secretory/Endocytic Pathway Facilitates Immune Recognition by CD4+ Cytotoxic T Lymphocytes: a Novel Approach to Vaccine Design , 1998, Journal of Virology.
[40] V. Cerundolo,et al. Effect of epitope flanking residues on the presentation of N‐terminal cytotoxic T lymphocyte epitopes , 1999, European journal of immunology.
[41] A. Hill,et al. Optimization of a peptide-based protocol employing IL-7 for in vitro restimulation of human cytotoxic T lymphocyte precursors. , 1997, Journal of immunological methods.
[42] R. Webster,et al. DNA vaccines. , 1996, AIDS research and human retroviruses.
[43] H. Grey,et al. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. , 1995, Journal of immunology.
[44] K. Münger,et al. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A , 1988, Cell.
[45] D. Chargelegue,et al. Synergistic effect of immunization with a peptide cocktail inducing antibody, helper and cytotoxic T-cell responses on protection against respiratory syncytial virus. , 1999, The Journal of general virology.
[46] F. Marincola,et al. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] J. Peto,et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide , 1999, The Journal of pathology.
[48] I. Frazer,et al. Identification of B epitopes in human papillomavirus type 16 E7 open reading frame protein. , 1990, The Journal of general virology.
[49] A. Suhrbier,et al. Multi‐epitope DNA vaccines , 1997, Immunology and cell biology.
[50] D. Bigner,et al. Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.
[51] U. Koszinowski,et al. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein , 1991, Cell.